A common variant of CDKN2A (p16) predisposes to breast cancer

Journal of Medical Genetics

Volumn 42, Issue 10, 2005, Pages 763-765

  Debniak T ^b   Gorski B ^b   Huzarski, T ^b   Byrski, T ^b   Cybulski, C ^b   Mackiewicz, A ^d   Gozdecka Grodecka, S ^d   Gronwald, J ^b   Kowalska, E ^b   Haus, O ^d   Grzybowska, E ^e   Stawicka, M ^f   Swiec, M ^g   Urbanski K ^h   Niepsuj, S ⁱ   Wasko B ^j   Gozdz S ^k   Wandzel, P ^l   Szczylik, C ^m   Surdyka, D ⁿ   Rozmiarek, A ^o   Zambrano, O ^p   Posmyk, M ^q   Narod, Steven A ^a,c   Lubinski, J ^b   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF TORONTO   (Canada)

^d Department of Cancer Immunology ^*  (Poland)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f Prophylactic and Epidemiology Center   (Poland)

^g Regional Hospital   (Poland)

^h INSTITUTE OF ONCOLOGY   (Poland)

ⁱ Regional Oncology Hospital   (Poland)

^j Regional Hospital Rzeszow   (Poland)

^k HOLYCROSS CANCER CENTER   (Poland)

^l Regional Hospital   (Poland)

^m Military Hospital Warszawa   (Poland)

ⁿ Regional Hospital   (Poland)

^o Regional Oncology Hospital   (Poland)

^p Regional Hospital   (Poland)

^q Regional Hospital   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; PROTEIN P16;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE PREDISPOSITION; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLAND; PRIORITY JOURNAL;

ADULT; ALLELES; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; ODDS RATIO; POLAND; RISK; VARIATION (GENETICS);

EID: 26944461595     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2005.031476     Document Type: Article

References (25)

1. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998;338:879-87.
2. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995;33:975-7.
3. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
4. Van Zee KJ, Calvano JE, Bisogna M. Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene 1998;16:2723-7.
5. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochem Biophys Acta 1998;1378:F115-77.
6. Schneider-Stock R, Giers A, Motsch C, Boltze C, Evert M, Freigang B, Roessner A. Hereditary p16-Leiden mutation in a patient with multiple head and neck tumors [letter]. Am J Hum Genet 2003;72:216-18.
7. Smigiel R, Sasiadek M, Krecicki T, Ramsey D, Jagielski J, Blin N. Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx. Mol Carcinog 2004;39:147-54.
8. Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, Schorderet D, Bosman FT, Chaubert P. Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest 2001;81:217-29.
9. Takahira T, Oda Y, Tamiya S, Yamamoto H, Kawaguchi K, Kobayashi C, Iwamoto Y, Tsuneyoshi M. Alterations of the p16INK4a/p14ARF pathway in clear cell sarcoma. Cancer Sci 2004;95:651-5.
10. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95:11891-6.
11. Debniak T, Gorski B, Scott RJ, Cybulski C, Medrek K, Zlowocka E, Kurzawski G, Debniak B, Kladny J, Bielecka-Grzela S, Maleszka R, Lubinski J. Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer. Int J Cancer 2004;110:558-62.
12. Lamperska K, Karezewska A, Kwiatkowska E, Mackiewicz A. Analysis of mutations in the p16/CDKN2A qene in sporadic and familial melanoma in the Polish population. Acta Biochim Pol 2002;49:369-76.
13. Debniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Debniak B, Zaluga E, Maleszka R, Kladny J, Gorski B, Cybulski C, Gronwald J, Kurzawski G, Lubinski J. CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 2005;65:835-9.
14. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000;92:1260-6.
15. Ghiorzo P, Ciotti P, Mantelli M, Heouaine A, Queirolo P, Rainero ML, Ferrari C, Santi PL, De Marchi R, Farris A, Ajmar F, Bruzzi P, Bianchi-Scarra G. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 1999;83:441-8.
16. Nielsen NH, Roos G, Emdin SO, Landberg G. Methylation of the p16(Ink4a) tumor suppressor gene 5′-CpG island in breast cancer. Cancer Lett 2001;163:59-69.
17. Gorgoulis VG, Koutroumbi EN, Kotsinas A, Zacharatos P, Markopoulos C, Giannikos L, Kyriakou V, Voulgaris Z, Gogas I, Kittas C. Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. Mol Med 1998;4:807-22.
18. Gorski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzanska A, Bebenek M, Fischer-maliszewska L, Grzybowska E, Narod SA, Lubinski J. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 2004;75:1131-5.
19. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gromwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymanska A, Szymanska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubinski J. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004;75:1131-5.
20. Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 1999;9:446-52.
21. Bertram CG, Gaut RM, Barrett JH, Pinney E, Whitaker L, Turner F, Bataille V, Dos Santos Silva I, J Swerdlow A, Bishop DT, Newton Bishop JA. An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. J Invest Dermatol 2002;119:961-5.
22. Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 1995;10:114-16.
23. Lilischkis R, Sarcevic B, Kennedy C, Warlters A, Sutherland RL. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer 1996;66:249-54.
24. Prowse AH, Schultz DC, Guo S, Vanderveer L, Dangel J, Bove B, Cairns P, Daly M, Godwin AK. Identification of a splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma prone kindred. J Med Genet 2003;40:e102.
25. Nichols KE, Malkin D, Garber JE, Fraumeni JF, Li FP Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001;10:83-7.